135 related articles for article (PubMed ID: 36068975)
1. Discovery of the Novel 1
Zhang XX; Xiao Y; Yan YY; Wang YM; Jiang H; Wu L; Shi JB; Liu XH
J Med Chem; 2022 Sep; 65(18):12095-12123. PubMed ID: 36068975
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia.
Zhang XX; Yan YY; Ma X; Xiao Y; Lei CC; Wang YM; Liu C; Wang Q; Zhang XT; Cheng WD; Liu XH
Eur J Med Chem; 2023 May; 251():115214. PubMed ID: 36889252
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy.
Yan YY; Zhang XX; Xiao Y; Shen XB; Jian YJ; Wang YM; She ZH; Liu MM; Liu XH
J Med Chem; 2022 Oct; 65(19):13216-13239. PubMed ID: 36126227
[TBL] [Abstract][Full Text] [Related]
4. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
5. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.
Chen Z; Wang Q; Yan YY; Jin D; Wang Y; Zhang XX; Liu XH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305852. PubMed ID: 38258519
[TBL] [Abstract][Full Text] [Related]
8. The discovery of a novel pyrrolo[2,3-b]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis.
Yan YY; Wang YM; Shen JH; Jian YJ; Lei CC; Wang Q; Liu C; Zhang XX; Liu XH
Biomed Pharmacother; 2024 Jun; 175():116705. PubMed ID: 38713949
[TBL] [Abstract][Full Text] [Related]
9. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells.
He L; Lu N; Dai Q; Zhao Y; Zhao L; Wang H; Li Z; You Q; Guo Q
Toxicology; 2013 Oct; 312():36-47. PubMed ID: 23907061
[TBL] [Abstract][Full Text] [Related]
10. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
Firestein R; Shima K; Nosho K; Irahara N; Baba Y; Bojarski E; Giovannucci EL; Hahn WC; Fuchs CS; Ogino S
Int J Cancer; 2010 Jun; 126(12):2863-73. PubMed ID: 19790197
[TBL] [Abstract][Full Text] [Related]
11. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
[TBL] [Abstract][Full Text] [Related]
13. Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors.
Martínez-González S; García AB; Albarrán MI; Cebriá A; Amezquita-Alves A; García-Campos FJ; Martínez-Gago J; Martínez-Torrecuadrada J; Muñoz IG; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2020 Sep; 201():112443. PubMed ID: 32599324
[TBL] [Abstract][Full Text] [Related]
14. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.
Kaur M; Velmurugan B; Tyagi A; Agarwal C; Singh RP; Agarwal R
Neoplasia; 2010 May; 12(5):415-24. PubMed ID: 20454513
[TBL] [Abstract][Full Text] [Related]
15. A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo.
Chen X; Yan Y; Cheng X; Zhang Z; He C; Wu D; Zhao D; Liu X
Bioorg Chem; 2023 Apr; 133():106402. PubMed ID: 36791618
[TBL] [Abstract][Full Text] [Related]
16. Role of CDK8 and beta-catenin in colorectal adenocarcinoma.
Seo JO; Han SI; Lim SC
Oncol Rep; 2010 Jul; 24(1):285-91. PubMed ID: 20514474
[TBL] [Abstract][Full Text] [Related]
17. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Philip S; Kumarasiri M; Teo T; Yu M; Wang S
J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
